TRX-813

TRX-813 is an investigational cancer therapeutic candidate being developed by TRX Biosciences. It represents a reprofiled (repurposed) anthelmintic (anti-parasitic) small molecule that utilizes the company's proprietary LipiCore™ oral drug delivery technology. This platform employs lipid-based formulations to facilitate drug absorption through the lymphatic system via chylomicrons, which allows the compound to bypass hepatic first-pass metabolism and achieve targeted delivery to tumors and specific tissues. While the specific active pharmaceutical ingredient and its molecular target have not been publicly disclosed, the drug is designed to exploit unexploited uptake channels to improve the bioavailability and efficacy of a compound that is otherwise poorly absorbed.